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had a BNP level > 100 during that time frame (Odds ratio
10.8, 95% CI (1.3 e 91.5)). Six patients (12%) died due to
transplant related mortality in the ﬁrst 100 days; 5 of these
(83%) had a BNP level >100 during the ﬁrst 14 days.
Conclusions: BNP levels peaked at Day +14 after allogeneic
HSCT in this study. Children who required critical care
resources (oxygen and PICU admission) almost invariably
demonstrated an elevated BNP during the ﬁrst 14 days after
HSCT. This information may be useful clinically and for risk
stratiﬁcation in studies of pediatric HSCT patients. The
etiology of the rise in BNP requires further study.Table 1
Patient Characteristics (n¼32)
Characteristic N (%)
Median age (range) 48 (20-62)
Diagnosis
AML/ALL/MDS/CML 3/5/7/3
CLL/NHL/Myeloma 2/6/4
Other 2
Donor source
Matched sibling 15 (47)
Matched unrelated 13 (41)
Mismatched unrelated / haploidentical / cord blood 4 (12)
Conditioning regimen
Myeloablative 19 (59)
Reduced intensity 13 (41)
Acute GVHD 14 (44)
Chronic GVHD 27 (84)
Patients on2 immunosuppressors at RSV diagnosis 21 (66)
Clinical syndrome
Upper tract infection 16 (50)
Pneumonia 16 (50)
Median days from transplant to RSV infection
(interquartile range)
382 (241 to 1049)292
Research qPCR Method for Engraftment Monitoring: A
6-Year Review of Proﬁciency Testing Results
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Diagnostics
A total of 40 samples were tested from 11 proﬁciency surveys
from 2006 through 2012 using samples from the American
Society for Histocompatibility and Immunogenetics (ASHI)
and the Post-SCT Chimerism Monitoring Programme of the
United Kingdom National External Quality Assessment
Schemes (UK NEQAS) for Leucocyte Immunophenotyping.
Sample percentage breakdown by reported means for the 39
ASHI samples is as follows: 3 did not consist of target cells
(0% samples), 5 consisted of target percentages from 5.7 to
22.28%, 8 consisted of target percentages from 26.2 to 49.2%,
20 consisted of target percentages from 51.2 to 95.93%, and 3
consisted only of target cells (100% samples). The single UK
NEQAS sample reported a median percentage of 94.70%.
Thirty-two of the forty samples (80%) consisted of target
percentages above 25%.
All 40 samples tested to date have received passing results
with our research qPCR method. For the three 0% samples
from 3 separate surveys, our qPCRmethod gave a result of 0%
for each sample while the STR PCR method gave a result
other than 0% in 14 instances. For the three 100% samples
from 3 separate surveys, our qPCR method gave a result of
100% for each samplewhile the STR PCRmethod gave a result
other than 100% in 10 instances.
It is not until recently (2012), that more than 1 or 2 testing
sites in the ASHI proﬁciency testing program have used
a qPCRmethod. The last ASHI survey of 2012 and the ﬁrst and
current UK NEQAS trial of the 2012-2013 schedule both
included 4 sites using qPCR. The qPCR method is a valuable
tool capable of studying chimerism far below the levels
attained by STR PCR (e.g. microchimerism < 1%). As the
number of sites using qPCR potentially increases, proﬁciency
testing organizations should include lower percentage
samples in order to adequately test the lower sensitivities
attainable with the qPCR method.
While ASHI participation began in 2006, it was not until 2010
that speciﬁc mention of our qPCR approach appeared in the
summary report. In the latest ASHI survey (2012 EMO-2), it
was recognized in the summary report that both conven-
tional (STR PCR) and qPCR assays can be used successfully
based on the comparable performance of the methods. Six
years of proﬁciency testing participation lends concrete
evidence that our research qPCR method is a viable alter-
native to the STR PCR approach offering unmatched sensi-
tivity while maintaining high accuracy and reproducibility
with low to high percentage samples.293
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Background: Respiratory syncytial virus (RSV) is a poten-
tially life threatening infection in allogeneic stem cell
transplant (Allo) recipients. Viral respiratory tract infections
have also been implicated in bronchiolitis obliterans (BO)
and other post Allo non-infectious pulmonary complications
(NIPCs). Since 2000, we have treated RSV infections in Allo
patients (pts) in a standardized manner with pre-established
criteria. We sought to determine survival of such uniformly
treated pts and to ascertain their risk of subsequent NIPCs.
Methods: Allo pts were systematically tested for RSV if they
presented with evidence of lower respiratory tract infection
or upper respiratory tract symptoms and predeﬁned risk
factors for RSV pneumonia. Pts received inhaled ribavirin 2 g
q8h  15 doses and standard IVIG 500 mg/kg/day  4 days
(d) if they exhibited any of the following features: 1) neu-
tropenia, 2) pneumonia, 3) active treatment for GVHD. Data
from 1/00 to 6/12 were collected retrospectively and ana-
lysed on an “intent-to-treat” basis.
Results: We present the ﬁrst 32 pts; their characteristics are
shown in Table 1. Of those with RSV pneumonia, one died 17
d after diagnosis (case fatality rate 6.3%; 95%CI: 0.2-30.2%)
after receiving partial treatment in the context of palliative
care for relapsed leukemia. In total, 13 pts died (40.6%; 95%
CI: 23.7-59.4%). Causes of death other than RSV included
GVHD (n¼4), relapse (n¼5), fungal and bacterial
pneumonia (n¼2), ARDS (n¼1) and other (n¼1). Median OS
from RSV infection was 53 months (m) (95%CI: 22 m-not
reached). Four pts had been diagnosed with BO 9 to 251
d prior to RSV. Among the 28 at risk for developing BO, the
incidence was 0% (95%CI: 0-12.3%). One was diagnosed
with cryptogenic organizing pneumonia 36 d after RSV
(3.4%; 95%CI: 0-18.3%).
